Patients should report new joint pain, unusual fatigue, signs of infection, or changes in RA symptoms promptly to their care team
Key readouts include: TRIUMPH-1 (obesity): Participants on the 12 mg weekly dose achieved an average body-weight reduction of roughly 28.3% at 80 weeks and up to 30.3% at 104 weeks , figures that approach outcomes previously associated only with bariatric surgery
Link(The Times) Fat jabs slash risk of silent killer which affects thousands
Lilly's March 2026 FAQ says retatrutide is available only to people in Lilly clinical trials, so if you are searching retatrutide availability, the answer is still trial-only
Health effects of overweight and obesity
What is known: because unregulated injectable peptides may harbor contaminants, youre taking a chance on your health if you use one